Advanced search×

Non-Invasive In Vivo Imaging of Tumor-Associated CD133/Prominin.

Chizuko Tsurumi, Norbert Esser, Elke Firat, Simone Gaedicke, Marie Follo, Martin Behe, Ursula Elsässer-Beile, Anca-Ligia Grosu, Ralph Graeser, and Gabriele Niedermann

PLoS One 5(12):e15605 (2010) PMID 21187924

DOI: 10.1371/journal.pone.0015605
Version: za2963e q8zad q8zbf q8zcc q8zd8 q8ze6 q8zf6 q8zga
View PDF

Similar articles you may find interesting…

  1. Efficient tumor targeting with high-affinity designed ankyrin repeat proteins: effects of affinity and molecular size.
    Christian Zahnd, Martin Kawe, ... Andreas Plückthun

    Cancer Res 70(4):1595-605 (2010) PMID 20124480

    We show here that with very small high-affinity proteins such as designed ankyrin repeat proteins (DARPins), these limits can be overcome. We have systematically investigated the influence of molecular mass and affinity on tumor accumulation with DARPins with specificity for HER2 in SK-OV-3.ip nude...
  2. A contemporary review of stereotactic radiotherapy: inherent dosimetric complexities and the potential for detriment.
    Michael L ML Taylor, Tomas T Kron, and Rick D RD Franich

    Acta Oncol 50(4):483-508 (2011) PMID 21288161

    Abstract Objective. The advantages of highly localised, conformal treatments achievable with stereotactic radiotherapy (SRT) are increasingly being extended to extracranial sites as stereotactic body radiotherapy with advancements in imaging and beam collimation. One of the challenge...
  3. Adnectin CT-322 inhibits tumor growth and affects microvascular architecture and function in Colo205 tumor xenografts.
    Maximilian Ackermann, Irvith M Carvajal, ... Moritz A Konerding

    Int J Oncol 38(1):71-80 (2011) PMID 21109927

    Antiangiogenesis has become a promising pillar in modern cancer therapy. This study investigates the antiangiogenic effects of the PEGylated Adnectin™, CT-322, in a murine Colo-205 xenograft tumor model. CT-322 specifically binds to and blocks vascular endothelial growth factor receptor (VEGFR-2)....